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The core promoter mutants of hepatitis B virus (HBV) emerge as the dominant viral population at the late
HBeAg and the anti-HBe stages of HBV infection, with the A1762T/G1764A substitutions as the hotspot
mutations. The double core promoter mutations were found by many investigators to moderately enhance viral
genome replication and reduce hepatitis B e antigen (HBeAg) expression. A much higher replication capacity
was reported for a naturally occurring core promoter mutant implicated in the outbreak of fulminant hepatitis,
which was caused by the neighboring C1766T/T1768A mutations instead. To systemically study the biological
properties of naturally occurring core promoter mutants, we amplified full-length HBV genomes by PCR from
sera of HBeAg individuals infected with genotype A. All 12 HBV genomes derived from highly viremic sera
(5  109 to 5.7  109 copies of viral genome/ml) harbored wild-type core promoter sequence, whereas 37 of 43
clones from low-viremia samples (0.2  107 to 4.6  107 copies/ml) were core promoter mutants. Of the 11
wild-type genomes and 14 core promoter mutants analyzed by transfection experiments in human hepatoma
cell lines, 6 core promoter mutants but none of the wild-type genomes replicated at high levels. All had 1762/
1764 mutations and an additional substitution at position 1753 (T to C), at position 1766 (C to T), or both.
Moreover, these HBV clones varied greatly in their ability to secrete enveloped viral particles irrespective of the
presence of core promoter mutations. High-replication clones with 1762/1764/1766 or 1753/1762/1764/1766
mutations expressed very low levels of HBeAg, whereas high-replication clones with 1753/1762/1764 triple
mutations expressed high levels of HBeAg. Experiments with site-directed mutants revealed that both 1762/
1764/1766 and 1753/1762/1764/1766 mutations conferred significantly higher viral replication and lower HBeAg
expression than 1762/1764 mutations alone, whereas the 1753/1762/1764 triple mutant displayed only mild
reduction in HBeAg expression similar to the 1762/1764 mutant. Thus, core promoter mutations other than
those at positions 1762 and 1764 can have major impact on viral DNA replication and HBeAg expression.
The hepatitis B virus (HBV) core gene is divided into the
precore region (29 amino acid codons) and the core region
(181 codons) by two in-frame initiating ATG codons. The
heterogeneity at the 5 end of the core gene transcript enables
initiation of translation from either the precore or core ATG
codon to express two related proteins. The major core gene
transcript (pregenomic RNA) has the 5 end downstream of
the precore ATG codon and thus can express core (nucleo-
capsid) protein only, whereas a subset of transcript (precore
mRNA) has its 5 end located upstream of the precore region
to express a longer protein form, the precursor to hepatitis B
e antigen (HBeAg). Efficient translational initiation from pre-
core ATG codon prevents core protein expression from this
subset of mRNA species. Maturation of HBeAg requires two
proteolytic cleavage events en route the secretory pathway.
The N-terminal 19 residues of this 210-amino-acid (i.e., 29 plus
181 amino acids) protein target the nascent protein to the
endoplasmic reticulum, where it is cleaved off. The C-terminal
arginine rich sequence of 34 residues is removed subsequently
by a furin-like protease during passage through the Golgi ap-
paratus. Thus, the mature HBeAg protein differs from core
protein by 10 extra residues at the N terminus and lacks of the
C-terminal DNA-binding sequence. Formation of intramolec-
ular disulfide bond between two cysteine residues (precore
residue 26 and core residue 61) generates the unique second-
ary structure of HBeAg distinct from core protein (35, 53).
Although multiple copies of core protein assemble to form
nucleocapsid essential for the packaging of pregenomic RNA,
as well as for virion formation, HBeAg is not required for HBV
replication in vitro (50). HBeAg homologue is also dispensable
for infectivity of related duck and woodchuck hepatitis viruses,
although it is necessary for persistent infection in woodchucks
(7, 8, 43). Expression of HBeAg during perinatal infection has
been proposed to promote immune tolerance (33). By sharing
antigenic epitopes with the core protein, HBeAg may serve as
a decoy to buffer anti-core protein immune response, which
develops soon after infection. On the other hand, once the host
develops an anti-HBe immune response, HBV-infected hepa-
tocytes are destroyed through membrane-bound HBeAg.
Thus, seroconversion from HBeAg to anti-HBe is usually as-
sociated with a 2-log reduction in the viremia titer. At the same
time, the anti-HBe immune pressure provides a strong selec-
tive force for the emergence of viral variants that express less
or no HBeAg.
Thus far, two types of HBeAg variants have been described:
the precore mutants and the core promoter mutants. HBeAg
expression is abolished in the precore mutants at the transla-
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tional level by nonsense or frameshift mutation, or mutated
initiation codon in the precore region, a region outside the
core protein coding sequence. The core promoter mutants
were discovered by Okamoto et al. (37), which harbor muta-
tions (mostly substitutions) in the basic core promoter region.
These mutations are clustered within the region from positions
1750 to 1770 of the HBV genome, with an A-to-T mutation at
1762 and a G-to-A mutation at 1764 being the most common
(1, 10–12, 17, 19, 23, 32, 37, 44, 48). When introduced into
wild-type HBV genomes, the double mutation indeed de-
creased HBeAg expression and, surprisingly, also enhanced
viral genome replication of about twofold (5). Later work from
others has confirmed this finding (3, 34, 42). The reduction of
HBeAg expression is apparently mediated by reduced precore
mRNA transcription, while the mechanism of enhanced repli-
cation might be complex, involving both transcription factor
binding and mutated HBx protein (25). The differential effect
of the naturally occurring mutations on the transcription of
precore versus pregenomic RNA is supported by the similar
impact of some artificial mutations (55). Consistent with their
different degrees of HBeAg downregulation, core promoter
mutations are detectable at the late HBeAg phase of infection,
whereas the precore mutations are found later, at the height of
anti-HBe immune response (Fig. 1). However, the core pro-
moter mutations are usually maintained after the rise of pre-
core mutations, implying a function other than modulating
HBeAg expression.
Isolated analysis on the effect of two hotspot mutations in
the core promoter region may have limitations, since many
different combinations of core promoter mutations are present
in patients (1, 10–12, 17, 19, 23, 32, 37, 44, 48). In this regard,
a core promoter mutant that caused an outbreak of fulminant
hepatitis replicated in human hepatoma cell lines at a level 10
times higher than did a wild-type control (18, 28). Interestingly,
two less-common core promoter mutations at 1766 (C to T)
and 1768 (T to A) were implicated in the high-replication
phenotypes (2, 3). Considering the importance of core pro-
moter mutants as the predominant viral species in the late
stage of HBV infection, we performed comparative transfec-
tion experiments of 14 naturally occurring core promoter mu-
tants with 11 wild-type clones and analyzed viral replication,
virion secretion, and expression of HBeAg and HBsAg.
MATERIALS AND METHODS
Serum samples and PCR. Serum samples were collected retrospectively from
13 French patients positive for HBeAg (based on the Abbott assay). Six individ-
uals had ca. 5  109 copies of genome/ml, and seven others had ca. 0.2  107 to
4.6  107 copies/ml as determined by branched DNA assay (Bayer Diagnostics).
The alanine aminotransferase levels were not significantly different between the
two groups (Table 1). When rechecked with the enzyme immunoassay kit from
Diasorin and 40-l serum samples, the HBeAg titer was found to be low for the
sample derived from patient 4 and borderline positive for the serum from patient
8 (Table 1). The serum samples were diluted in TEN buffer (10 mM Tris [pH
8.0], 1 mM EDTA, 100 mM NaCl) and digested at 37°C for 2 h with proteinase
K (0.5 mg/ml) in the presence of sodium dodecyl sulfate (SDS; 0.5%). DNA was
extracted with phenol-chloroform-isoamyl alcohol (25:24:1) and precipitated
with ethanol. Purified DNA was resuspended in water. Full-length HBV
genomes were amplified according to the method of Gunther et al. (16).
For efficient directional cloning of the PCR products, we modified sense prim-
er into 5-CCGGAAAGCTTATGCTCTTCTTTTTCACCTCTGCCTAATCA
TC-3 (the HindIII site is underlined) and antisense primer into 5-CCGGA
GAGCTCATGCTCTTCAAAAAGTTGCATGGTGCTGGTG-3 (the SacI site
is underlined). Forty cycles of amplification were performed with the Expand
high-fidelity PCR system (Roche).
Cloning and dimer construction. The PCR products were cloned into the
HindIII/SacI sites of pUC18 vector. For HBV transcription to proceed under the
control of endogenous core promoter, tandem dimers were made. The HBV
insert was released from pUC18 vector by digestion with SapI and BglI, circu-
larized with T4 DNA ligase, and relinearized with EcoRI. Next, HBV DNA with
EcoRI ends were ligated to EcoRI-digested, dephosphorylated pUC18 DNA at
an insert/vector ratio of at least 10:1. After transformation, colonies harboring
tandem HBV dimers were screened with an oligonucleotide probe spanning the
tail-to-head junction as described previously (51). The oligonucleotide has the
sequence 5-GGCCATGCAGTGGAATTCCACWRCYTTCCA-3 (W  A 
T; R  A  G; Y  C  T).
Site-directed mutants. Mutations in the core promoter region were introduced
by overlap extension PCR, by using Expand high-fidelity PCR system and fewer
than 25 PCR cycles. The PCR products were digested with RsrII and ApaI
restriction enzymes to exchange with the cognate fragment in clone 2A. The
entire PCR-derived fragment was sequenced to guarantee the lack of unwanted
mutations. Tandem dimeric version of the mutants was prepared.
FIG. 1. Diagram of the dynamic change of viral populations during
seroconversion from HBeAg to anti-HBe. The seroconversion is ac-
companied by rapid drop in viremia titer. The wild-type (WT) HBV
population declines and eventually disappears as a result of the selec-
tive pressure of anti-HBe immunity, whereas the core promoter mu-
tants (CPM) and precore mutants (PCM) arise sequentially to replace
the wild-type HBV. We propose that the highly viremic samples used
in the present study were at an early HBeAg stage of infection,
whereas the low-viremia samples were close to seroconversion.
TABLE 1. Correlation between viremia titer and prevalence
of core promoter mutantsa
Patient
no.
Viremia level
(106/ml)
HBeAgb
titer
Transaminase
(ULN)
No. of clones with
CPM/total no. of
clones tested
1 7 15,956 1.54 7/8
2 33 12,891 2.12 2/3
3 2 ND 1.54 2/5
4 43 528 1.5 6/6
8 32 97 0.82 6/7
9 46 16,739 2.54 11/11
14 22 17,824 ND 3/3
5 5,700 15,585 1.33 0/2
6 5,700 14,611 1.17 0/2
7 5,700 12,452 3.12 0/2
11 4,960 20,648 2.33 0/2
12 5,700 13,468 ND 0/2
13 5,700 15,243 1.8 0/2
a Abbreviations: CPM, core promoter mutations; ULN, upper limit of normal
levels; ND, not determined.
b The value for the negative control was 150.
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Transfection and detection of HBV replication. Dimeric HBV DNA was trans-
fected into the Huh7 and HepG2 human hepatoma cells by a calcium phosphate
transfection kit (5 Primer-3 Primer or Promega), with 15 g of HBV dimer per
10-cm dish or 8 g per 6-cm dish. After incubation of the cells with DNA
precipitates for 4 to 6 h, cells were washed and replaced with fresh medium. Cells
were harvested by trypsin or scrapping at 5 days posttransfection with no interim
medium change, and culture supernatant was collected. HBV core particles were
obtained from cell lysate and treated with nuclease as described previously (52).
Cells were lysed with 300 l of buffer containing 10 mM HEPES (pH 7.5), 100
mM NaCl, 1 mM EDTA, and 1% NP-40. The lysate was supplemented with 10
mM CaCl2–12 mM MgCl2 and digested at 37°C for 15 min with DNase I (1.5 U)
and mung bean nuclease (20 U) to degrade transfected HBV DNA. Core par-
ticles were precipitated with 110 l of polyethylene glycol (PEG) solution (1.2 M
NaCl, 60 mM EDTA, 30% sucrose, 26% PEG), resuspended in 100 l of solution
containing 10 mM Tris (pH 7.5)–6 mM MgCl2–8 mM CaCl2, and digested with
1.5 U of DNase I and 2.5 U of mung bean nuclease at 37°C for 10 min to further
degrade transfected DNA. After the addition of 270 l of protease digestion
buffer (25 mM Tris [pH 7.5], 10 mM EDTA, 100 mM NaCl, 0.5% SDS), samples
were digested at 37°C for 2 h with proteinase K (0.5 mg/ml). DNA was extracted
with phenol and precipitated with ethanol. Purified DNA was subjected to
Southern blot analysis with a highly pure full-length HBV probe (obtained by two
rounds of PCR amplification). Gel electrophoresis was either performed in the
absence of ethidium bromide or in its presence both in the gel and in the running
buffer, which greatly accelerated migration of the single-stranded HBV genome.
Strand-specific HBV probes. Single-stranded RNA probes were used to con-
firm the nature of HBV genomes associated with intracellular core particles and
extracellular particles. We have recently sequentially subcloned a 2.2-kb EcoRV-
EcoRI fragment and a 2.6-kb EcoRI-ApaI fragment (with ApaI end flushed) of
clone 3.4 into the SmaI-XhoI (flushed) sites of pBluescript vector for studies on
virion secretion. This subclone was digested to completion with EcoRI and then
transcribed with T7 polymerase to generate 2.6-kb negative-stranded riboprobe
or with T3 polymerase to generate 2.2-kb positive-stranded RNA probe (Ribo-
probe In Vitro Transcription Systems; Promega), with [-32P]CTP (3,000 Ci/
mmol) as a radioactive tracer. Template DNA was subsequently degraded by
RNase-free DNase, and the probe was purified by phenol-chloroform extraction
and Sephadex G-50 column chromatography. Diethyl pyrocarbonate-treated so-
lutions were used during hybridization and washing steps.
Analysis of extracellular viral particles. Culture supernatant was prespun at
4,000 rpm for 10 min to remove cell debries and loaded on top of 10 and 20%
sucrose (in TEN buffer). Samples were spun at 39,000 rpm for 18 h with a Sorvall
SW41 rotor to pellet extracellular particles. It should be noted that this proce-
dure collects both Dane particles and naked core particles. Transfected HBV
DNA was digested away at 37°C for 15 min by 1 U of DNase I and 1.5 U of mung
bean nuclease in the presence of 8 mM CaCl2 and 6 mM MgCl2. The proteinase
K digestion buffer (270 l) was added, and samples were digested at 37°C for 2 h
with proteinase K (0.5 mg/ml). DNA was extracted with phenol and precipitated
with ethanol in the presence of 20 g of glycogen as a carrier. HBV DNA was
detected by Southern blot. Gel electrophoresis was performed in the presence or
absence of ethidium bromide.
Further separation of Dane particles from naked core particles was achieved
by sedimentation through CsCl gradient as previously described (50). After
concentration of viral particles from culture supernatant through a 10 and 20%
sucrose cushion, particles in the pellet fraction were resuspended in 4.5 ml of
TEN solution. CsCl (1.5 g) was added and dissolved, and samples were spun at
12°C and 46,000 rpm for 48 h or longer in a Sorvall SW65 rotor. Fractions of 400
l were taken from the top and weighed to obtain density values. After dialysis
against TEN buffer, an aliquot from each fraction (10 to 15 l) was used for
HBsAg measurement, and the remaining solution was used for DNA extraction.
Each sample was supplemented with 8 mM CaCl2 and 6 mM MgCl2 and digested
with 1 U of DNase I and 1.5 U of mung bean nuclease at 37°C for 10 min. Tris
(pH 7.5), EDTA, and SDS were added to final concentrations of 25 mM, 10 mM,
and 0.5%, respectively, and proteins were digested with 0.5 mg of proteinase
K/ml. After phenol extraction and ethanol precipitation, DNA was analyzed in
Southern blot.
HBsAg and HBeAg. The HBsAg secreted into the culture supernatant was
measured by using the Auszyme kit from Abbott Laboratories. Secreted HBeAg
was detected by the enzyme immunoassay kit from Diasorin. The samples were
diluted four times or more to avoid signal saturation.
RESULTS
Experimental approaches. Our original goal was to identify
naturally occurring HBV genomes with high- and low-replica-
tion capacities, with the long-term prospect of mapping the
trans- or cis-acting elements that regulate viral replication lev-
els. HBeAg samples were selected, and the full-length HBV
genomes were amplified. Assuming a positive correlation be-
tween viral titers and intrinsic replication capacities of the viral
strains, we studied samples with either highest or lowest vire-
mia levels (Table 1). The patients infected with the same ge-
notype were selected so as to avoid potential genotypic differ-
ence in replication capacity. Genotype A was chosen since it
is the most common HBV genotype in HBeAg patients in
France (15, 26). The limited sequence variability within this
particular genotype (usually 2%) would simplify the subse-
quent identification of underlying mutations. The patients
were not under antiviral therapy at the time of sample collec-
tion. Although HBV replication can proceed (to various ex-
tents) from different DNA constructs, including vector-free
circularized or linear genome (16), vector-linked tandem
dimer (52), and a DNA copy of pregenomic RNA under for-
eign (cytomegalovirus) promoter, we selected to pursue the
tandem dimer approach. Such a DNA form allows HBV rep-
lication to proceed under the endogenous core promoter
rather than an artificial cytomegalovirus promoter and thus
permits the expression of HBeAg. This turned out to be judi-
cious, since all of the high-replication genomes identified in the
present study are core promoter mutants. Core promoter mu-
tations modulate HBV replication and HBeAg expression at
the transcriptional level (5, 34, 42).
Due to the quantitative nature of the work, measures were
taken to ensure the accuracy of the results. HBV dimers were
purified with the same plasmid DNA purification kit, and DNA
concentrations determined by a spectrometer were validated
by gel electrophoresis after HindIII digestion. Transfection
efficiency was monitored by cotransfection with genes encoding
glycine decarboxylase (27) or luciferase. Each panel of con-
structs was tested at least three times, and similar results were
obtained. For site-directed core promoter mutants derived
from clone 2A, levels of HBsAg expression (which is not ex-
pected to be modulated by core promoter mutations) were
used as an internal control for the transfection efficiency.
Frequent isolation of core promoter mutants from low-vire-
mia sera positive for HBeAg. We initially sequenced the core
promoter region of a total of 12 full-length HBV genomes
derived from six patients: three (patients 5, 6, and 7) with high
levels (5.7  109 copies/ml) and three (patients 2, 3, and 4)
with low levels of viremia (0.2  107 to 4  107 copies/ml)
(Table 1). Of the six clones derived from low-viremia sera (2A,
2B, 3.4, 3.10, 4B, and 4D), all but 2A and 3.10 had core
promoter mutations (Fig. 2). In contrast, none of the six clones
derived from highly viremic serum (5.2, 5.4, 6.1, 6.2, 7.2, and
7.4) had core promoter mutations. The prevalence of core
promoter mutants in less-viremic samples suggests that these
patients may be close to seroconversion to anti-HBe, which is
associated with both the emergence of core promoter mutants
and a decrease in viremia (Fig. 1). To substantiate this finding,
we sequenced 8 more clones from patients 2 to 4, 29 clones
from four more low-viremia samples (patients 1, 8, 9, and 14),
and 6 clones from three additional high-viremic patients (pa-
tients 11, 12, and 13) (Table 1). All six new clones from highly
viremic samples also possessed a wild-type sequence in the
core promoter, whereas 33 of 37 genomes from low-titer sam-
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ples had core promoter mutations (Table 1 and Fig. 2). Taken
together, all 12 clones derived from six highly viremic sera were
of the wild-type sequence, whereas 37 of 43 clones derivd from
the seven sera with low viremia levels had core promoter mu-
tations.
Some core promoter mutants have very high replication
potential. We initially tested 12 HBV genomes (4 core pro-
moter mutants and 8 wild-type clones) for replication capacity
in transfected Huh7 cells. Three clones (4D, 5.4, and 6.1) failed
to replicate or to express HBeAg (Fig. 3A), and sequencing of
the core gene revealed deletion of a single nucleotide (2088 for
5.4 and 6.1; 2324 for 4D). Clone 4B and, to a lesser extent,
clone 3.4 replicated at much higher levels than the other ge-
nomes (Fig. 3A, panel of intracellular particles). Similar results
were obtained in repeat experiments (data not shown) and in
another HCC cell line, HepG2 (Fig. 3B, panel of intracellular
particles). Both clones contained the 1762T 1764A common
core promoter mutations. In addition, clone 3.4 harbored the
1753C mutation, whereas clone 4B had 1753C and 1766T mu-
tations. To correlate the replication capacity with the type of
core promoter mutations, we prepared 10 additional tandem
dimers of core promoter mutants and 3 dimers of wild-type
clones. The 10 core promoter mutants covered seven different
types of core promoter mutations (Fig. 2 and 4). Four addi-
tional highly replicating genomes were identified: 1B, 4C, 4F,
and 8.22 (Fig. 4, panels of intracellular particles). Of these, 1B
contained the same triple core promoter mutations as clone 3.4
(1753C 1762T 1764A), 4C and 4F had the same four point
mutations (1753C 1762T 1764A 1766T) as clone 4B derived
from the same individual, and 8.22 harbored 1762T 1764A
1766T triple mutations (three of the four substitutions as ob-
served in 4B). Clone 8.22 also had two additional point muta-
tions further upstream: T1636G/C1678T. A quantitative anal-
FIG. 2. Core promoter sequences found in HBV clones derived
from HBeAg serum samples with high- or low-viremia titers. (A) Se-
quence patterns at 1751 to 1777 of the basic core promoter region.
Pattern 1 represents the wild-type sequence. Hyphens indicate a lack
of nucleotides at these positions. Patterns 2 to 8 contained only sub-
stitutions. Insertions were present in patterns 9 to 11, and deletions
occurred in sequences under patterns 12 and 13. The most common
substitutions at 1762 and 1764 are marked by asterisks. (B) HBV
clones with such divergent sequence patterns. For each clone, the
number at the beginning identifies the patient (clone 1.2 was derived
from patient 1, whereas clone 2A was from patient 2). It is evident that
dominant viral populations from patients 1, 4, and 9 had patterns 3, 4,
and 7, respectively.
FIG. 3. Transfection of 12 HBV genomes in Huh7 cells (A) and
HepG2 cells (B). Cells grown in 10-cm dishes were transfected with 15
g of HBV dimer and 15 g of duck glycine decarboxylase (DGD)
cDNA (24) and then harvested 5 days later. From the cell lysates, duck
glycine decarboxylase expression was determined by Western blotting,
and HBV DNA replication was detected by Southern blot from core
particles. From the culture supernatant, HBsAg (shown as the optical
density at 490 nm) and HBeAg (shown as counts per minute [103])
were measured by commercial kits after 1:4 and 1:5 dilution of sam-
ples, respectively. Extracellular viral particles (both Dane particles
and naked core particles) were concentrated by ultracentrifugation
through sucrose cushions and analyzed by Southern blotting. Various
amounts of 3.2-kb linear HBV DNA were run in parallel as a size
marker and for quantification. CP mutation, core promoter mutations;
ds, double-stranded viral genome; ss, single-stranded viral genome.
Gels were run in the absence of ethidium bromide (A) or in its pres-
ence (B). The two “ds” bands in panel B may represent relaxed circular
DNA and duplex linear DNA, respectively, whereas the “ds” band in
panel A appears to be duplex linear.
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ysis in Huh7 cells revealed that 4B replicated 8-fold higher
than 2A, a genome with wild-type core promoter sequence,
whereas 3.4 replicated at least 4-fold more efficiently than 2A
(Fig. 5A, panel of core particles). In another experiment in-
volving 4B, 1B, and 8.22, the replication capacities of clone 1B
and 4B were estimated to be eightfold higher than for clone
11.4 and even higher than for clone 12.2 (Fig. 5B). Further-
more, clone 8.22 replicated at an even higher level. Both clones
11.4 and 12.2 had a wild-type core promoter sequence.
Core promoter mutants vary greatly in their rates of virion
secretion. HBV DNA replication is asymmetric. The negative
strand is synthesized first from the pregenomic RNA template
and, after degradation of the RNA template, positive-strand
DNA is synthesized by using the negative-strand DNA as a
template (13, 47). Only core particles containing such double-
stranded viral genome are enveloped and secreted into serum
(13), although human hepatoma cell lines transfected with
HBV DNA may release naked core particles containing single-
stranded genome (14, 54, 57). Parallel to the detection of
replicating viral DNA within transfected cells, we concentrated
extracellular viral particles (both enveloped virus particles and
naked core particles) by ultracentrifugation and analyzed par-
ticle-associated HBV DNA by Southern blot. Clone 4B was
found to release many more viral particles than did other HBV
genomes, especially clone 3.4, by comparing the relative inten-
sities of extratracellular viral DNA with intracellular viral
DNA (Fig. 3A). This point is better demonstrated by serial
dilution of both intracellular and extracellular viral DNA de-
rived from clones 3.4 and 4B (Fig. 5A). Similar degrees of
difference can be found between 4B and two other high-repli-
cation clones, 1B and 8.22 (Fig. 5B). On the other hand, two
wild-type genomes with low replication capacities displayed
elevated extracellular viral DNA signals compared to most
other clones (clone 5.2 in Fig. 3 and clone 11.4 in Fig. 4 and 5).
Therefore, release of particles to culture medium did not cor-
relate with core promoter mutations (Table 2).
Ultracentrifugation through 10 to 20% sucrose will pellet
down both Dane particles and naked core particles. Surpris-
ingly, extracellular particles produced from clones 1B, 2B, 3.4,
4C, 7.2, and 8.22 displayed mainly the single-stranded form,
whereas both DNA forms were produced by many other clones
(Fig. 3 to 5). Since naked core particles released by human
hepatoma cell lines usually contain single-stranded viral ge-
nome (14, 54, 57), we separated core particles from Dane
particles through CsCl gradient. Indeed, clones such as 4B, 5.2,
and 6.2 released two types of particles, with a double-stranded
genome inside lighter Dane particles and a single-stranded
genome inside heavier core particles (Fig. 6). In contrast,
clones 2B, 3.4, and 7.2, which had primarily singled-stranded
FIG. 4. Transfection of 14 HBV genomes in Huh7 cells. Cells were
harvested at day 5 posttransfection. For released viral particles, a short
exposure is also given to better visualize the bands corresponding to
single- and double-stranded viral genomes. ds,: double- stranded viral
genome; ss, single-stranded viral genome.
FIG. 5. Quantitative analysis of the relative replication and secre-
tion capacities of different HBV clones. (A) Comparison of clones 2A,
3.4, and 4B. (B) Comparison of clones 1B, 2A, 4B, 8.22, 11.4, and 12.2.
Huh7 cells were transfected with various HBV constructs and har-
vested at day 5 posttransfection. HBV DNA from intracellular core
particles and extracellular viral particles were analyzed, with the aga-
rose gels run in the absence of ethidium bromide. The entire samples
of 2A, 11.4, and 12.2 were loaded into single wells, while serially di-
luted samples of 1B, 3.4, 4B, and 8.22 were loaded into separate lanes.
ds, double-stranded viral genome; ss, single-stranded viral genome.
Please note that clones 3.4 and 1B and, to a lesser extent, clone 8.22,
released viral particles with predominantly single-stranded viral ge-
nome despite a similar ratio of the two DNA forms inside intracellular
core particles.
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DNA in the culture supernatant (Fig. 3), released essentially
core particles with single-stranded DNA (Fig. 6). Since the
release of naked core particles with single-stranded genome is
an artifact of hepatoma cells, our results suggest high virion
secretion efficiency of clones 4B and 5.2 and much reduced
virion secretion by clones 1B, 2B, 3.4, 7.2, and 8.22.
The two major HBV DNA bands were closely spaced if
separated in agarose gels lacking ethidium bromide (compare
panels A and B in Fig. 3; clone 7.2 against other clones in Fig.
6). To confirm the fast-migrating band as negative-stranded
HBV genome, we separated intracellular and extracellular vi-
ral DNA of clones 4B and 3.4 in triplicate and hybridized strips
of blots with negative-stranded riboprobe, positive-stranded
riboprobe, and double-stranded DNA probe, respectively. The
extracellular viral particles were resolved into naked core par-
ticles and Dane particles by CsCl gradient. Linear HBV DNA
of 3.2, 1.7, and 1.5 kb were included as size markers. Consid-
ering that the positive strand is present only in double-stranded
genomes, the negative-stranded probe should hybridize to dou-
ble-stranded DNA only. On the other hand, the positive-
stranded riboprobe and the double-stranded DNA probe will
hybridize to both DNA species. This was indeed the case (Fig.
7). The single-stranded DNA migrated much slowly in the
absence of ethidium bromide (to a position above 2 kb) than in
its presence (to 1.5 kb). The double-stranded DNA was pri-
marily linear (ca. 3.2 kb) in Huh7 cells, whereas more relaxed
circular DNA (running at around 4kb position) was generated
in HepG2 cells (Fig. 3B versus A; clone 4B in Fig. 6 versus
right panels of Fig. 7). Whether derived from HBV 3.4 or 4B,
extracellular naked core particles contained primarily nega-
tive-stranded HBV DNA, whereas Dane particles had only
double-stranded DNA (Fig. 7). This is consistent with the
presence of a “maturation signal” for virion formation and
secretion (47).
Sustained HBeAg expression by some core promoter mu-
tants. Besides viral DNA detection, we also measured secre-
tion of HBsAg and HBeAg to culture medium. Several clones,
e.g., 4C, 4D, 8.29, 14.3, 1B, 3.4, and 9.27, expressed no or little
HBsAg (Fig. 3 and 4). Clones 4D, 5.4, 6.1, and 8.30 were
defective in HBeAg expression (Fig. 3 and 4) owing to a frame-
shift mutation in the core gene, whereas the lack of HBeAg
expression by clones 2B and 8.12 was attributable to a precore
region deletion (at position 1827) and a TAG nonsense muta-
tion (codon 28), respectively. Several core promoter mutants
(8.22, 4B, 4C, 4F, 8.29, and 9.27) expressed very low levels of
HBeAg (Fig. 3 and 4). However, clones 1B and 3.4 and, to a
lesser extent, clones 1.6 and 9.24 expressed high levels of
HBeAg (Fig. 3 and 4 and Table 2). Clones derived from patient
9 belonged to the South African subgroup of genotype A as
previously described (4).
FIG. 6. CsCl gradient separation of naked core particles from
Dane particles. Culture supernatants from 10-cm dishes of Huh7 or
HepG2 cells were subjected to ultracentrifugation in 10 to 20% su-
crose gradient to pellet the viral particles, which were further spun in
CsCl gradient. Fractions of 400 l were collected, dialyzed, and DNA
extracted for Southern blot analysis with an HBV DNA probe (for
samples with a high-secretion phenotype, only fractions of DNA sam-
ples were used for Southern blotting). The results shown for clones 3.4
and 4B were from an experiment in HepG2 cells, whereas data for the
other clones were obtained from transfected Huh7 cells. Except for
clone 7.2, gels were run in the presence of ethidium bromide to better
separate the single-stranded genome from the double-stranded ge-
nome. For clones 3.4 and 4B, the density values of the CsCl fractions
were determined. The HBsAg values were measured for CsCl fractions
of other samples. Note that clones 3.4, 7.2, and 2B secreted very few
Dane particles. HBV, 3.2-kb HBV genome; ss, single-stranded viral
genome.
TABLE 2. Properties of some naturally occurring
genotype A strains
Clone
Core
promoter
pattern
DNA
replication
Virion
secretiona
HBeAg
expression
HBsAg
expression
Full-length
sequence
2A 1     Yes
5.2 1     No
7.2 1  /	   No
11.4 1     No
9.24b 2     No
1B/3.4 3  /	 c /	 Yes
4B 4     Yes
4C 4  /	  	 No
8.12 4   	d  No
1.6 5     No
8.22 6     Yes
9.27b 7    /	 No
a Based on the intensity the of extracellular double-stranded DNA relative to
intracellular double-stranded DNA.
b South African subgroup of genotype A, with precore codons 17 and 25
mutated to TTT and GGA, respectively.
c Even higher in HepG2 cells.
d Contains a TAG nonsense mutation at precore codon 28.
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Limited sequence divergence among HBV genomes with dif-
ferent replication and secretion phenotypes. As the initial step
toward understanding the structural basis for the diverse rep-
lication, secretion, and HBeAg expression phenotypes, we de-
termined the complete nucleotide sequences of five HBV ge-
nomes. Clone 2A has a wild-type core promoter sequence and
replicated at a low level. In contrast, clones 1B, 3.4, 4B, and
8.22 are core promoter mutants with high replication capaci-
ties. Among these, clones 1B and 3.4 have low-virion-secretion
and high-HBeAg-expression phenotypes; 4B has high-virion-
secretion and low-HBeAg-expression phenotypes; 8.22 has
low-secretion and low-HBeAg phenotypes. All five clones con-
tained a genome size of 3,221 nucleotides characteristic of
genotype A (Fig. 8). Sequence differences were only 36 nucle-
otides (1.1%) between clones 2A and 3.4, 46 nucleotides
(1.4%) between clones 2A and 4B, 54 nucleotides (1.7%) be-
tween clones 2A and 8.22, 43 nucleotides (1.3%) between
clones 3.4 and 4B, 50 nucleotides (1.6%) between clones 3.4
and 8.22, and 56 nucleotides (1.7%) between clones 4B and
8.22. Clone 1B turned out to have the same sequence as clone
3.4. These two clones have mutated pre-S2 initiation codon
and will not express the middle envelope protein.
Cumulative effect of core promoter mutations on viral rep-
lication and HBeAg expression. In order to determine the
extent to which different core promoter mutations contribute
to the different replication and HBeAg expression phenotypes
of naturally occurring mutants, we generated four site-directed
mutants from clone 2A (Fig. 9A). After transfection into
Huh7 cells, viral DNA replication and HBeAg expression were
determined. Since the mutations are not expected to affect
HBsAg expression, we used HBeAg/HBsAg ratios (after sub-
traction of values from nontransfected cells) to accurately de-
termine the effect of various core promoter mutations on
HBeAg expression. Results from seven independent experi-
ments revealed a moderate effect of 1762/1764 hotspot muta-
tions on HBeAg expression (mu1). The expression of HBeAg
was further reduced by the addition of the 1753 mutation
(mu4) and, more potently, by the 1766 mutation (mu2a). In-
troduction of all four point mutations (Ex2) reduced HBeAg
expression to the level of 4B, the naturally occurring core
promoter mutant (Fig. 9C). Similarly, viral DNA replication
was enhanced by the hotspot mutations (mu1), augmented by
the 1753/1762/1764 mutations (mu4) and, more effectively, by
the 1762/1764/1766 mutations (mu2a) or the four point muta-
tions together (Ex2) (Fig. 9B).
DISCUSSION
The core promoter mutants are the predominant viral spe-
cies at the late HBeAg phase and the anti-HBe stage of
infection. Characterization of their biological and pathogenic
properties is essential for therapeutic interventions. Extensive
clinical studies have attempted to correlate core promoter mu-
tants with HBeAg status or level, viremia titer, liver diseases,
and response to antiviral therapy (1, 6, 11, 19, 20, 23, 30). Due
to the presence of viral quasispecies, the complexity of the host
immune system, and the difficulty of assessing the cause-effect
relationship, conflicting results have been reported. In this
regard, functional characterization of the core promoter mu-
tants in human hepatoma cell lines permits the evaluation of
their biological properties. Up to now, most investigators have
taken the approach of introducing the core promoter muta-
tions into the background of a wild-type genome and have
focused on the 1762T 1764A hotspot mutations (5, 34, 42, 49,
56). These mutations reduce HBeAg expression and slightly
increase viral DNA replication. In contrast, a naturally occur-
ring core promoter mutant associated with fulminant hepatitis
outbreak displayed a 10-fold-higher replication capacity than
the wild-type clone, as a result of 1766T 1768A core promoter
mutations, rather than the common 1762T 1764A mutations (2,
3, 18, 28). The present study sought to characterize large num-
ber of naturally occurring core promoter mutants, together
with naturally occurring wild-type isolates. A complex pattern
of viral DNA replication, viral secretion, and HBeAg and
HBsAg expression was observed for these core promoter mu-
tants (see Table 2 for summary).
Viremia titer and prevalence of core promoter mutants.
Consistent with reports in the literature (1, 6, 11, 20, 37), we
could detect core promoter mutants from HBeAg patients.
Such mutants are highly prevalent in genotype A strains owing
FIG. 7. Detection of intracellular and extracellular HBV DNA by
strand-specific probes. Huh7 cells were transfected with HBV clones
3.4, 4B, and 5.4 (as a negative control). DNA was isolated from intra-
cellular core particles, triplicate DNA samples were separated in aga-
rose gels in the presence or absence of ethidium bromide as indicated,
and hybridized with one of the three probes. Extracellular viral parti-
cles were separated by CsCl gradient, and fractions with densities of
Dane particles (D) and core particles (C) were pooled. DNA was
separated in an agarose gel in the presence of ethidium bromide and
hybridized with one of the three probes. HBV DNA linearized with
EcoRI (3.2 kb) and EcoRI plus RsrII (1.7 plus 1.5 kb) were run in
parallel as size markers. More DNA samples of clone 3.4 were added
than 4B. ds, double stranded; ss, single stranded.
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to their reduced tendency to develop the HBeAg-minus pre-
core mutation (6, 26, 29, 31, 40). Interestingly, distribution of
core promoter mutants segregated with viremia titer: no such
mutants were found in highly viremic sera, whereas a high
prevalence of such mutants was detectable in samples with
much-reduced viremia (Table 1). Similar observations, though
not as clearcut as ours, were made with HBeAg samples
covering the entire spectrum of viremia titer (11, 30). It is well
established that the level of viremia declines over the course of
HBV infection, especially during the period of seroconversion
from HBeAg to anti-HBe (Fig. 1). We propose that the highly
viremic samples were still at the early HBeAg stage of infec-
tion, while the low-titer samples were already approaching the
period of seroconversion (Fig. 1).
Effect of less-common core promoter mutations on viral
replication and HBeAg expression. Eight HBV genomes with
wild-type core promoter sequence (2A, 3.10, 5.2, 6.2, 7.2, 7.4,
11.4, and 12.2) showed evidence of DNA replication, but none
FIG. 8. Comparison of the complete nucleotide sequences of HBV clones 2A (top), 4B (second), 3.4 (third), and 8.22 (bottom). These se-
quences are available in GenBank under accession numbers AF536524, AF537372, AF537371, and AY152726. The translational start sites for
envelope, core, HBx, and polymerase protein are indicated.
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replicated at high levels. In contrast, six core promoter mutants
(4B, 4C, 4F, 3.4, 1B, and 8.22) replicated at much higher rates,
and all harbored the common A1762T/G1764A mutations. In
addition, there was a T1753C mutation in clones 1B and 3.4
and a C1766T mutation in clone 8.22. Both mutations were
found in 4B, 4C, and 4F genomes (clone 8.12 failed to replicate
at high level despite identical mutations as found in 4B). Site-
directed mutagenesis not only confirmed the role of 1762/1764
common mutations on viral DNA replication but also demon-
strated the importance of the less-common mutations, espe-
cially the C1766T mutation (Fig. 8B, mu2a and Ex2). This
result is consistent with previous work with the fulminant hep-
atitis strain, although for that strain the 1766 mutation alone
enhanced replication by twofold only (2, 3). We did not test the
FIG. 9. Effect of different combinations of core promoter mutations on HBV genome replication and HBeAg expression. (A) Site-directed
mutants. Clone 4B contains four point mutations in the core promoter compared with clone 2A. Mu1, mu2a, mu4, and Ex2 are clone 2A-based
site-directed mutants containing different mutation combinations. Mutated nucleotides are shown in boldface. (B) Results from one transfection
experiment. Huh7 cells grown in 6-cm dishes were transfected with 10 g of HBV DNA and 2 g of luciferase plasmid and then harvested 5 days
later. The values of luciferase were determined from cell lysate. HBsAg and HBeAg values were determined from culture supernatant. (C) HBeAg
expression profiles of the mutants. We used HBeAg/HBsAg ratios to minimize the effect of variation in transfection efficiency. The graph is based
on results from seven independent experiments in Huh7 cells. Mu2a and Ex2 displayed highest degree of viral DNA replication and the lowest level
of HBeAg expression. Their replication and HBeAg expression phenotypes are close to those of the naturally occurring core promoter mutant,
clone 4B.
FIG. 8—Continued.
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effect of 1766 mutation alone in the present study. Based on
the results of site-directed mutants, we conclude that the high
replication capacity of clones 4B (4C and 4F) and 8.22 is at
least partly contributed by the combined core promoter muta-
tions but is not due to the 1762/1764 mutations alone.
Findings with the site-directed mutants may also partly ex-
plain why naturally occurring core promoter mutants varied
greatly in HBeAg expression. The 1762/1764 hotspot muta-
tions (mu1) and 1753/1762/1764 triple mutations (mu4) re-
duced HBeAg expression only moderately in genotype A,
whereas the 1762/1764/1766 mutations (mu2a) and 1753/1762/
1764/1766 quadruple mutations (Ex2) markedly suppressed
HBeAg production (Fig. 9A). In agreement with these find-
ings, the HBeAg expression level was high for 9.24 (1762/1764)
and 1B/3.4 (1753/1762/1764) but much lower for 4B (1753/
1762/1764/1766) and 8.22 (1762/1764/1766). Consistent with
these observations, only serum samples from patients 4 and 8
showed low or no HBeAg expression (Table 1). The domi-
nance of 1753/1762/1764/1766 quadruple mutations in patient
4 was evidenced by their presence in clones 4B, 4C, 4F, 4G, and
4H (though not in 4D).
What is the mechanism whereby the core promoter muta-
tions in clones 4B (or Ex2) and 8.22 (or mu2a) markedly
enhance viral replication and reduce HBeAg expression? The
1762/1764/1766 mutations (shared by Ex2 and mu2a) are lo-
cated in the nuclear receptor-binding site of the core promoter,
which is part of X gene coding sequence. In this regard, the
1762/1764 hotspot mutations cause a double amino acid
change in the HBx protein, which suppresses the transcription
of both precore and pregenomic RNA (25). The double mu-
tation also creates a new HNF1 binding site, which specifically
enhances pregenomic RNA transcription (25). The net effect is
specific reduction in the transcription of precore but not pre-
genomic RNA. Recent studies from Tang et al. (49) found that
RXR-PPAR binding and enhancement of viral transcrip-
tion and/or replication are abrogated by the double mutations,
whereas the transcription-enhancing effect of HNF4 is main-
tained and even augmented. A weak effect of the HNF1 on
transcription was also demonstrated. Since the HNF1-binding
site created by the 1762/1764 double mutation is imperfect
(GGTTAATGATC) compared to the 1762/1764/1766 triple
mutations (GGTTAATGATT), the stronger replication and
lower HBeAg expression by the triple mutant could be caused
by a better response to HNF1. Indeed, other types of core
promoter sequences shown in Fig. 2, including those with both
1766 and 1768 mutations, do not completely conform to this
optimal HNF1 consensus sequence. Interestingly, naturally oc-
curring HBV strains with HNF1-binding sites (as a result of
insertions) have been identified and found to possess enhanced
pregenome transcription and viral replication (17, 39). We
plan to formally test this hypothesis in the near future.
The paradox of enhanced in vitro replication and reduced in
vivo viremia. Contrary to our initial hypothesis, high replicat-
ing viral strains were isolated from patients with diminished
viremia titer, while serum with a high viral titer contained viral
strains with limited replication capacity in hepatoma cell lines.
Nevertheless, a high replication capacity of core promoter mu-
tants is consistent with their frequent association with fulmi-
nant hepatitis (12, 21, 28, 32, 36, 41, 44, 45), and one such
genome associated with fulminant hepatitis was found to rep-
licate at a very high level (2, 18). Our results suggest that very
high replication potential is a feature shared by many naturally
occurring core promoter mutants rather than limited to core
promoter mutants implicated in fulminant hepatitis. Thus, the
real question is why patients infected with core promoter mu-
tants fail to produce high viremia. We cannot exclude the
possibility that viral replication in hepatoma cell lines might be
quantitatively different from that in normal hepatocytes, con-
sidering that transcription factors such as RXR-PPAR and
HN4 promote the replication of wild-type HBV and core pro-
moter mutants differentially (49, 56). One may also argue that
the high replicating clone may constitute a minor fraction of
viral quasispecies in vivo. However, most clones derived from
patient 4 had the identical core promoter mutations (1753C
1762T 1764A 1766T) associated with high replication capacity.
A third possibility is a decline in virion secretion, as exempli-
fied by core promoter mutants 1B, 3.4, and 8.22. Finally, we
believe reduced viremia associated with core promoter mu-
tants could be explained by enhanced destruction of viral par-
ticles by the host immune system. Consistent with the high
replication capacity of core promoter mutants, genotype C of
HBV causes more severe liver diseases than genotype B and
develops core promoter mutations much more frequently than
genotype B (9, 22, 30, 38, 46).
Core promoter mutants differ greatly in virion secretion.
Comparison among different clones revealed great variability
in the intensity of extracellular HBV DNA relative to intracel-
lular DNA. Although most clones released both double- and
single-stranded genomes, clones such as 3.4 failed to release
double-stranded genomes. CsCl gradient centrifugation and
strand-specific probes revealed an association of extracellular
single (negative)-strand DNA with core particles and of dou-
ble-stranded DNA with Dane particles. The fact that naked
core particles were detected from virtually all of the clones
suggests constitutive nature of its release in Huh7 cells, either
as a result of cell death or through a specific release mecha-
nism (considering similar amounts of double- and single
stranded HBV DNA intracellularly for most clones). Since the
release of naked core particles does not occur in vivo, virion
secretion efficiency can be easily estimated by comparing the
double-stranded DNA species inside cells and in culture me-
dium. Thus, clones such as 4B, 11.4, and 8.12 displayed much
higher secretion efficiencies than clones 3.4, 1B, and 8.22 (Fig.
5), although we do not know whether 4B has an increased
secretion capacity, whether 3.4 has a decreased secretion ca-
pacity, or whether both are true. It is anticipated that high viral
replication coupled with limited viral secretion in the long-
living hepatocytes will cause marked viral retention and may
trigger severe liver diseases.
The molecular basis for the altered secretion capacities re-
mains to be determined. Recently, Le Pogam et al. (24) re-
ported reduction in virion secretion by naturally occurring sub-
stitutions at the core protein (Pro5Thr and Leu60Val). In
another study, amino acid substitutions in the small envelope
protein reduced secretion of both viral and subviral particles
(21). Taken together, these results highlight the importance of
core-envelope interaction in virion formation and secretion.
The mutations described by these investigators are absent in
clone 3.4, although this clone does express a reduced level of
HBsAg (Fig. 3 and 4). However, our ongoing mapping exper-
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iment suggests that the defects in HBsAg secretion and virion
secretion are genetically separable (N. Khan et al., unpub-
lished data). In summary, the present study establishes much
higher replication capacities of some naturally occurring core
promoter mutants compared to their wild-type counterparts.
Such highly replicating core promoter mutants differ greatly in
the efficiency of HBeAg and HBsAg expression and virion
secretion. The replication and HBeAg expression profiles are
controlled, at least in part, by the overall pattern of their core
promoter mutations. In particular, increased viral DNA repli-
cation and reduced HBeAg expression brought by the hotspot
1762T 1764A mutations are augmented by the C1766T muta-
tion.
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